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Abstract
Von Hippel-Lindau (VHL) inactivation develops a tumor syndrome characterized by highly
vascularized tumors as a result of hypoxia inducible factors (HIF) stabilization. The most common
manifestation is the development of hemangioblastomas typically located in the central nervous
system and other organs including the liver. PTEN (Phosphatase and tension homologue deleted on
chromosome 10) inactivation also upregulates HIF-1α and may take part in promoting vascular
lesions in tumors. The coordinate effect of loss of these tumor suppressors on HIF levels, and the
subsequent effect on vascular lesion formation would elucidate the potential for mechanisms to
modify HIF dosage supplementally and impact tumor phenotype. We therefore employed models of
somatic conditional inactivation of Vhl, Pten, or both tumor suppressor genes in individual cells of
the liver by Cre-loxP recombination to study the cooperativity of these two tumor suppressors in
preventing tumor formation. Nine months after tumor suppressor inactivation, Vhl conditional
deletion (VhlloxP/loxP) mice showed no abnormalities, Pten conditional deletion (PtenloxP/loxP) mice
developed liver steatosis and focal nodular expansion of hepatocytes containing lipid droplet and fat.
Vhl and Pten conditional deletion (VhlloxP/loxP; PtenloxP/loxP) mice, however, developed multiple
cavernous liver lesions reminiscent of hemangioblastoma. Liver hemangioblastomas in VHL disease
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may, therefore, require secondary mutation in addition to VHL loss of heterozygosity which is
permissive for vascular lesion development or augments levels of HIF-1α.
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Introduction
Von Hippel-Lindau (VHL) syndrome is an autosomal dominant multi-system disorder
characterized by abnormal growth of blood vessels and angiogenic tumors. The most common
manifestation is hemangioblastomas typically located in the central nervous system and other
organs including liver [1,2]. VHL syndrome is caused by mutation of VHL gene on the short
arm of the third chromosome (3p25). Most patients with VHL disease inherit one mutant copy
of VHL gene from one parent and somatically lose the wild type allele, consistent with the
tumor suppressor gene “two hit hypothesis” [3]. Somatic VHL loss contributes to the
development of sporadic cancers as well, in particular clear cell type renal cell carcinoma [4,
5]. VHL loss contributes to tumorigenicity by permitting the post-translational stabilization of
the hypoxia inducible factors (HIF-1α and HIF-2α) [6]. The HIF factors facilitate the
transcription of a wide repertoire of hypoxia response genes which promote angiogenesis and
tumor growth.
Phosphatase and tension homologue deleted on chromosome 10 (PTEN), a tumor suppressor
gene in a variety of tumors, is implicated in the familial Cowden syndrome [7]. Its inactivation
permits activation of AKT (also known as protein kinase B, PKB) phosphorylation and
subsequent induction of downstream HIF-1α protein translation and may take part in
angiogenesis and vascular lesions in tumors. Additionally, loss of PTEN has been shown to
play a role in increasing the transcriptional activation induced by HIF-1α by a mechanism that
is independent of AKT phosphorylation [8].
It is not known whether these distinct mechanisms of HIF regulation operate only as parallel
means to achieve the same HIF response, or if the degree of HIF activation can be modulated
and have potential to impact tumor phenotype. Within the context of VHL mutation, we have
observed a graded effect of HIF disregulation with missense mutations as compared to the null
allele [9,10]. The combined loss of VHL and PTEN is observed in some tumors, suggesting
that there may be non-overlapping roles of these two tumor suppressors in modulating
tumorigenesis. We therefore sought to understand if effects of PTEN loss on HIF regulation
and activity could enhance the already increased levels of HIF in a VHL null setting.
Mice homozygous for the Vhl null allele are lethal at embryonic midgestation due to placenta
vascular abnormalities [11]. To circumvent the embryo's lethality of Vhl gene knockout, mice
carrying a loxP-flanked Vhl allele (VhlloxP/loxP) were generated and the Cre-loxP technique
was used to conditionally inactivate Vhl gene [12]. Although several research groups have
generated mouse and tissue specific mice models using conditional Vhl inactivation, Vhl
somatic loss and the subsequent effects on lesion formation or tumorigenesis have not been
examined [12–15].
In order to investigate the cumulative effect of postnatal somatic Vhl and Pten loss on HIF
expression and the development of vascular lesions, we developed a modified self-
complementary Adeno-associated virus carrying Cre recombinase (scAAV-Cre) [16,17]. The
vector was introduced by tail vein injection into adult mice with one of a panel of conditional
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tumor suppressor gene knockout backgrounds: Vhl allele (VhlloxP/loxP), Pten allele
(PtenloxP/loxP), or both Vhl and Pten alleles (VhlloxP/loxP;PtenloxP/loxP). Loss of either tumor
suppressor alone gave a mild, but distinct phenotype, however, VhlloxP/loxP;PtenloxP/loxP mice
developed multiple cavernous vascular liver lesions reminiscent of hemangioblastoma.
HIF-1α and HIF-2α levels were highly upregulated in these vascular lesions, although they
were barely detectable throughout the liver of mice conditional loss of only one tumor
suppressor Vhl or Pten. This model demonstrates that dual strategies to engage pro-angiogenic




A recently constructed AAV2 vector plasmid, pHpa-Trs-SK [16,17], was used to produce the
self-complementary AAV2 viral vector (scAAV-GFP) containing a human cytomegalovirus
(CMV) promoter and an enhanced GFP gene (Fig. 1a). This construct packages only dimeric
inverted repeat genomes. The scAAV-Cre vector plasmid carrying Cre recombinase was
constructed from pHpa-Trs-SK. First, GFP was removed from pHpa-Trs-SK plasmid by
digesting with AgeI and NotI. Then, 1,032 bp of the Cre cassette was amplified from the
plasmid pCAAGS-Cre [18] by PCR, using the following primers: 5′Cre XmaI (5′-ATC CCC
CCG GGA TGT CCA ATT TAC TGA CCG TA-3′) and 3′Cre NotI (5′-ATA AGA ATG CGG
CCG CCT AAT CGC CAT CTT CCA-3′). XmaI and NotI restriction enzyme sites were added
to the 5′ and 3′ ends, respectively during the PCR. This fragment was inserted into the pHpa-
Trs-SK vector with the Rapid DNA Ligation Kit (Roche, Basel, Switzerland). The structure
of the scAAV-Cre plasmid (Fig. 1b) was confirmed by restriction digestion and sequence
analysis performed by the Automated DNA Sequencing Facility at the University of North
Carolina at Chapel Hill. The recombinant AAV viral vectors used in this study were prepared
in 293T cells using three-plasmid co-transfection, and purified following previously published
methods [19] by the Vector Core Facility, Gene Therapy Center, University of North Carolina
at Chapel Hill.
Mouse genetics and in vivo administration of vectors
All mice used in this study were bred and maintained in the Laboratory Animal Facility of
University of North Carolina at Chapel Hill using protocols approved by the UNC institutional
animal care and use committee. ROSA26 lox-stop-lox-LacZ reporter mice (Jackson
Laboratories, Bar Harbor, ME) [20] and C57BL/6 mice with a loxP-flanked Pten allele
(PtenloxP/loxP) were kindly provided by Dr. T. Van Dyke [21]. BALB/c mice with a loxP-
flanked Vhl allele (VHLloxP/loxP) were kindly provided by Dr. Volker Haase [12].
VhlloxP/loxP mice were intercrossed with PtenloxP/loxP mice to generate
VhlloxP/wt (wildtype);PtenloxP/wt mice. These VhlloxP/wt;PtenloxP/wt mice were subsequently
intercrossed to generate VhlloxP/loxP;PtenloxP/loxP mice, which were mixed genetic background
(BALB/c, C57BL/6), littermates were used as controls.
ROSA26 lox-stop-lox-LacZ reporter mice were intravenously (I.V.) injected with a total of
1011 particles of scAAV empty capsid, or scAAV-GFP or scAAV-Cre vector in a final volume
of 100 μl with a 30-gauge needle via tail vein. The ROSA26 reporter mice were sacrificed at
4 weeks after the injection and organs including liver, kidney, spleen, heart, and lung were
harvested for analysis of reporter gene expression.
VhlloxP/loxP, PtenloxP/loxP, VhlloxP/loxP;PtenloxP/loxP mice or control littermates were injected
via the tail vein with 1011 particles of scAAV empty vector, or scAAV-Cre vector in a final
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volume of 100 μl at the age of 6 weeks. Animals were euthanized at a time point 9 months
after the injection and autopsied for phenotype evaluation.
The VhlloxP/wt alleles were detected by PCR amplification of the loxP site, yielding 400 and
200 bp products for the floxed and wildtype alleles, respectively using the primers: Vhl forward
1 (5′-CCG GAG TAG GAT AAG TCA GCT GAG-3′) and Vhl reverse (5′-CTG ACT TCC
ACT GAT GCT TGT CAC AG-3′). The PCR condition was 94°C for 10 min (min), 35 cycles
of 94°C 50 s, 58°C 50 s, and 72°C 1 min, and 72°C 5 min extension. Detection of
PtenloxP/wt alleles yielded 435 and 310 bp products for the floxed and wildtype alleles using
the primers: Pten forward (5′-TGT TTT TGA CCA ATT AAA GTA GGC TGT G-3′) and
Pten reverse (5′-AAA AGT TCC CCT GCT GAT GAT TTG T-3′). The PCR condition was
94°C for 2 min, 34 cycles of 94°C 20 s, 62°C 45 s, and 72°C 45 s, and 72°C 2 min extension.
Products were resolved in 1.5% agarose gels and visualized with ethidium bromide under UV
light.
PCR analysis of recombination
Microdissection of hemangiomas was performed using a laser capture microdissection (LCM)
system. 4 μm sections from formalin fixed and paraffin embedded tissue were used after
dewaxing in xylene and drying. The dissected tissue was transferred into 25 μl of proteinase
K buffer and incubated with proteinase K at 56°C overnight, followed by inactivation of
proteinase K at 95°C for 10 min. 5 μl was used for subsequent PCR to detect recombined
Vhl using the following primers: forward 2 (5′-CTG GTA CCC ACG AAA GTG TC-3′) and
Vhl reverse (5′-CTG ACT TCC ACT GAT GCT TGT CAC AG-3′) yielding a 250 bp product
for the recombined Vhl allele (Fig. 3d) [12]. For the detection of recombined Pten, the following
primers were used for PCR: primer 1 (5′-AAA AGT TCC CCT GCT GAT GAT TTG T-3′)
and primer 2 (5′-TTC CTT AGC CTG TTC CAG C-3′), which yielded an around 1 kb product
for the recombined Pten allele (Fig. 3e) [21].
Assays of reporter gene expression
To detect the expression of GFP, organs harvested from the scAAV-GFP vector injected mice
were embedded in Optional Cutting Temperature (OCT, Electron Microscopy Sciences,
Hatfield, PA), snap frozen, and sectioned on a cryostat (10 μm sections). Sections were
examined for GFP expression using a fluorescence microscope with a fluorescein filter set.
To examine the β-galactosidase expression, livers from the scAAV-Cre injected ROSA26
reporter mice were harvested, some tissue fixed in 10% formalin overnight, dehydrated in
gradient ethanol, embedded in paraffin, sectioned, and stained with hematoxylin and eosin
(HE), while other liver tissue was snap frozen and embedded in OCT for frozen sections, which
were stained using an X-gal staining kit pH 8.5, according to manufacturer's instructions
(Chemicon International, Temecula, CA). Sections were counterstained with eosin prior to
dehydration through gradient ethanol and xylene and were mounted using Cytoseal™ XYL
(Richard-Allan Scientific, Kalamazoo, MI).
Histological analysis and immunohistochemistry
The organs harvested from VhlloxP/loxP, PtenloxP/loxP, and VhlloxP/loxP;PtenloxP/loxP mice were
fixed in 10% formalin overnight, dehydrated in gradient ethanol, and embedded in paraffin. 4
μm sections were cut and stained with hematoxylin and eosin (HE) and Periodic Acid-Schiff
(PAS). Some harvested livers were snap frozen, embedded in OCT, sectioned on a cryostat,
and stained with oil red O.
Immunohistochemistry staining was performed on formalin fixed paraffin embedded sections
according to the protocol from Vector ABC Elite Kit. Antigen retrieval for all antibodies was
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done by boiling the slides in citrate buffer (pH 6.0; BioGenex) for 30 min. Endogenous
peroxidase activity was quenched in 3% H2O2 for 10 min. Antibodies used were: anti-
HIF-1α (Clone H1 alpha 67, mouse monoclonal antibody, 1:50, Novus), anti-HIF-2α (Clone
190b, mouse monoclonal antibody, 1:100, Gene-Tex), anti-Ki67 (Clone SP6, rabbit polyclonal
antibody, 1:200, Lab Vision Corporation), anti-phosphorylated AKT (p-AKT, Ser 473, 1:200,
Cell Signaling), anti-vascular epithelial growth factor (VEGF, A-20, SC-152, rabbit polyclonal
antibody, 1:100, Santa Cruz), and anti-platelet endothelial cell adhesion molecule 1 (PECAM,
CD31, rabbit polyclonal antibody, 1:50, Abcam). Detection for all antibodies was performed
using the Vector ABC Elite Kit and a Vector DAB kit for substrate detection (Vector Labs,
Burlingame, CA). Immunofluorescence detection followed the same protocol, except that
signal amplification used TSA Plus Fluorescence System (Perkin-Elmer, Wellesley, MA) and
slides were mounted with Vectashield Vector mount media (Vector Laboratories). Digital
images were captured with a Nikon DMX-1200 color digital camera using the ACT-1 software
(Nikon, Melville, NY).
Results
Intravenous gene delivery and recombination with scAAV
The scAAV viral system was developed to permit the induction of cre recombination in the
liver without invoking an immune response. Further, as the effect of gene loss on single cells
in an otherwise unperturbed environment was desired, a virus affecting a limited percentage
of cells in the liver was selected. To examine the effectiveness of scAAV transduction in the
liver and the stability of virally expressed proteins, the scAAV-GFP vector was injected into
mice via tail vein. The mice were euthanized 4 weeks after the injection and organs were
harvested, frozen, sectioned, and examined for the persistent expression of the GFP transgene
by fluorescence microscopy. At the dosage injected, GFP expression was visible in scattered
cells in the liver, transfecting around 20–30% of hepatocytes, but not in other organs (Fig. 1c
and data not shown). No GFP expression was observed in AAV2 empty capsid injected control
animals.
The scAAV vector system was modified to deliver Cre recombinase in order to expand the
potential for tissue specific transgenic induction. In order to visually evaluate the areas of
recombination, ROSA26 lox-stop-lox-LacZ reporter mice were subjected to in vivo delivery
of the scAAV-Cre vector. Organs were harvested and β-galactosidase staining was performed
at 4 weeks after the scAAV-Cre injection (Fig. 1d). The Cre-dependent recombination event,
monitored by β-galactosidase-positive staining, was observed in liver (Fig. 1d). Positive cells
were observed quite widely dispersed and around 30% hepatocytes were infected in the liver.
No LacZ activity was detected in other organs such as kidney, spleen, heart, and lung (data not
shown). There was no inflammatory cell infiltration in liver and other organs indicating no
immune response to the vector (Fig. 1e and data not shown).
Vhl and Pten loss cooperates to promote the development of vascular lesions
scAAV-Cre vector was injected into VhlloxP/loxP, PtenloxP/loxP, and VhlloxP/loxP; PtenloxP/loxP
mice via tail vein to investigate the potential for coordinate effects of inactivation of the tumor
suppressor genes Vhl and Pten. Grossly, the livers of VhlloxP/loxP or PtenloxP/loxP mice
displayed no visible abnormalities at 4, 9, and 12 months after the AAV-Cre vector injection.
However, VhlloxP/loxP;PtenloxP/loxP mice displayed large discrete lesions visible both on the
surface of the liver and within the liver parenchyma by 9 months after the AAV-Cre vector
injection (Fig. 2a–c). These gross anatomic lesions were only associated with combined loss
of Vhl and Pten.
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Histologically, conditional Vhl loss showed minimal abnormalities in liver (Fig. 2d, g), which
differed from prior studies with albumin-cre directed excision [12]. Pten loss, however,
produced a high penetrance of discrete liver nodules with disorganized cellular architecture,
and cells which displayed a vacuolated cytoplasm, surrounded by normal appearing hepatic
parenchyma. The edge of one such nodule is depicted in Fig. 2e, h. Additionally, hepatic
nodules displaying cells with marked atypia and basophilic cytoplasm were observed in a
subset of these animals (data not shown). When the genetic events were combined, histologic
examination of livers from VhlloxP/loxP;PtenloxP/loxP mice sacrificed 9 months after scAAV-
Cre vector administration detected expansile, highly vascular lesions with a complex cellular
architecture (Fig. 2f, i), in which some small blood vessels showed PECAM positive further
demonstrating angiogenesis may happen (Fig. 8c). None of the lesions associated with the
individual loss of Vhl or Pten were observed, as shown in Table 1, a summary of the findings
associated with each genotype was provided. These discrete vascular lesions corresponded to
the grossly visible nodules in the liver, and shared features of liver hemangioblastoma, although
at 9 months there was no evidence of local invasion or metastatic spread.
Hepatic vascular lesions show evidence of Vhl and Pten loss
PCR analysis of microdissected liver tissue from the highly vascular lesions associated with
the VhlloxP/loxP;PtenloxP/loxP genotype showed that the expected target Vhl and/or Pten alleles
were recombined and deleted, as indicated by recombination of the Vhl or Pten locus. A
representative PCR comparing the affected area of a highly vascular lesion with the expected
PCR products from tail genotype of the mouse is shown (Fig. 3).
Vhl and Pten loss leads to distinct patterns of lipid accumulation
Conventional loss of Vhl is associated with a cellular conversion to anaerobic metabolism and
an accumulation of cytoplasmic glycogen. In contrast, Pten loss, particularly in the liver, is
associated with an accumulation of cytoplasmic lipid. The bioenergetic effects of the combined
loss of these genes are unknown. Gross examination of the Pten mutant livers revealed
hepatomegaly, and histological analysis demonstrated that the mutant hepatocytes within the
nodules displayed large cytoplasmic vacuoles. A PAS stain for glycogen deposition was
applied to the affected livers and demonstrated some areas of glycogen deposition in the
VhlloxP/loxP livers, but little extra accumulation was observed in the PtenloxP/loxP livers.
However, less PAS staining was observed in the lesions present in VhlloxP/loxP;PtenloxP/loxP
mice (Fig. 4a–c).
Similarly, oil red O was used to stain for lipid in these livers, demonstrating minimal lipid
accumulation in the VhlloxP/loxP mice. As expected, the nodules present in PtenloxP/loxP mice
demonstrated marked accumulation of lipid, as did the highly vascular lesions of the
VhlloxP/loxP;PtenloxP/loxP mice (Fig. 4d–f). Intense lipid uptake was not observed in other
normal areas of the liver (data not shown).
Vhl and Pten loss additively affects cellular proliferation in livers of Vhl and Pten conditional
deletion mice
The distinct lesions associated with each genetic profile, and in particular the appearance of
nodule expansion, suggested that effects on cellular proliferation may be present. The
proliferative nuclear marker Ki67 was utilized to detect dividing cells in liver lesions associated
with each of the genotypes. Ki67 positive cells were significantly increased in the
PtenloxP/loxP liver nodules as compared with the VhlloxP/loxP lesions, and VhlloxP/loxP;
PtenloxP/loxP livers displayed the most apparent increase in proliferation compared to either
Pten or Vhl deleted alone (Fig. 5).
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Upregulated phosphorylated AKT expression in hepatic lesion of Vhl and Pten conditional
deletion mice
AKT is a downstream target of the PTEN regulated phosphatidylinositol 3 kinase (PI3K)
pathway, its phosphorylation serving as an indicator of PTEN loss. We examined the
localization of phosphorylated AKT using a phospho-specific immunofluorescence stain,
which showed that cytoplasmic phosphorylated AKT expression was induced in hepatocytes
in both the nodules of PtenloxP/loxP mice and the vascular lesions associated with
VhlloxP/loxP;PtenloxP/loxP mice (Fig. 6), verifying that upregulated phosphorylated AKT
induced by Pten loss was a signaling mechanism activated in both of the genotype specific
vascular lesions and fatty lesions.
Upregulated HIF-1α and HIF-2α expression in hepatic vascular lesions of Vhl and Pten
conditional deletion mice
pVHL protein is involved in the ubiquitination and degradation of the transcription factor
family members HIF-1α and HIF-2α. Loss of the pVhl protein results in stabilization of these
proteins, and subsequent upregulation of hypoxia response target genes, which play important
roles in regulating angiogenesis, cell growth, or cell survival [22]. In order to investigate the
impact of Vhl inactivation on downstream HIF-1α and HIF-2α stabilization in the pathogenesis
of vascular lesions in the VhlloxP/loxP;PtenloxP/loxP conditional deletion mice, HIF-1α and
HIF-2α were evaluated by immunofluorescence (Figs. 7, 8). In Vhl or Pten deletion mice,
HIF-1α and HIF-2α were under the level of detection in the liver except in isolated cells, even
in the presence of the genotype-specific lesions. Whereas the nuclear accumulation of both
HIF-1α and HIF-2α in these lesions confirms the additive events activated by Vhl and Pten
loss are present in this highly vascular lesions.
Upregulated PECAM and VEGF in hepatic vascular lesions of Vhl and Pten conditional
deletion mice
In order to investigate the angiogenesis in Vhl and Pten conditional deletion mice, we stained
the lesions for evidence of endothelial cell contribution with PECAM. In Vhl or Pten deletion
mice, PECAM was sporadically positive throughout the liver and limited to the endothelial
cells lining small vessels, whereas in Vhl and Pten conditional deletion mice, more PECAM
positive cells were present in the lesions, demonstrating the contribution of cells with
endothelial features to the overall mass (Fig. 9a–c).
VEGF is a downstream target of HIF-1 and HIF-2. In order to investigate the pathogenesis of
the highly vascular lesions observed in Vhl and Pten conditional deletion mice, we stained the
lesions for VEGF by immunohistochemistry. In Vhl or Pten single deletion mice, VEGF was
sporadically positive in the liver, whereas in the liver vascular lesions of Vhl and Pten
conditional deletion mice, there are more VEGF positive cells indicating that VEGF was
coordinately expressed with HIF factors, and likely contributes to the vascular phenotype of
the lesions as a result of HIF-1α and HIF-2α upregulation (Fig. 9d–f).
Discussion
The cooperative nature of concurrent loss of tumor suppressor genes raises many questions
regarding the mechanisms which promote tumor progression. We have used an in vivo gene
inactivation system to model the independent and concurrent loss of the tumor suppressors
Vhl and Pten. Both are predicted to cause pro-angiogenic features of tumor development as a
result of activation of HIF target genes, in the case of Vhl as a result of HIF stabilization, and
in the case of PTEN as a result of AKT dependent increase in HIF protein translation, as well
as an AKT-independent facilitation of HIF transcriptional activity. Whether quantitative effects
on HIF levels or HIF activity specifically influence the degree of vascular lesion production,
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or if HIF mediated effects occur as a result of surpassing a threshold of HIF activity, we have
demonstrated that the combined loss of Vhl and Pten leads to a highly penetrant phenotype of
expansile vascular lesion development in the liver.
We observed minimal pathological changes in the liver with Vhl loss alone, even after 1.5 years
of latency following the AAV-Cre vector injection. This finding contrasts with that observed
with either albumin or actin-cre induced Vhl recombination which promotes abundant loss of
Vhl in the liver occurring at an early developmental time point [12,13]. Loss of Vhl function
in single adult cells may be insufficient to induce lesion formation in the liver beyond rare
simple liver hemangiomas, or further progression may require signals from neighboring
affected cells. This model system is unique in restricting the genetic events to isolated cells
within the adult liver parenchyma, thus excluding contributions from neighboring genetically
modified cells or fields of genetically affected cells. Unique features of cellular organization
in embryogenesis may also contribute to the different effects seen in our model system which
is limited to adult animals. An alternate cause for these observations is that somatic abrupt loss
of Vhl alone may trigger cellular senescence, as reported by Young et al. [23], thus accounting
for the very minimal phenotype observed with Vhl loss alone.
Pten conditional deletion in our viral system consistently displayed the accumulation of round
fatty nodules and hepatocyte vacuoles surrounded by regions of normal liver. Analysis for
glycogen vs lipid accumulation in the lesions, confirmed that the Pten associated nodules
display a phenotype of lipid accumulation. This is reminiscent of the fatty cell accumulation
seen with widespread Pten loss in the liver, but suggests that the event of expansion of these
hepatocytes has a clonal origin.
In contrast to the mild phenotypes of the single deletions, most (13/15, 86%) mice with
combined inactivation of Vhl and Pten developed multiple macroscopically evident vascular
lesions indicating that Pten and Vhl act as synergistically pro-angiogenic events in the liver
lesion formation. Immunohistochemistry stain showed phosphor-ylated AKT upregulated in
the cells lining liver lesions resembling hemangioblastomas, confirming that Pten loss in these
lesions leads to the consequent constitutive activation of downstream components of the PI3K
pathway known to drive angiogenesis via HIF-1α [24,25]. Therefore, Pten loss induced
activated phosphorylated AKT combined with Vhl loss and the subsequent upregulated HIF
pathway cooperated to induce highly vascular liver lesions not observed as a result of either
event alone.
Both germline and somatic inactivation of the VHL tumor suppressor gene have been observed
in hemangioblastomas and clear cell renal carcinomas [26]. The pVHL protein is involved in
the ubiquitination and degradation of the transcription factors HIF-1α and HIF-2α, downstream
of mTOR signaling [27]. Thus, the lesions may form as a result of supraphysiological levels
of HIF-mediated signals, only sufficient with the combined loss of Vhl and Pten to promote
the formation of these lesions. Alternative explanations exist, including the possibility that
Vhl only acts as a tumor suppressor in the setting of a permissive environment and is not
sufficient to produce a growth promoting phenotype. Pten loss may provide a supplementing
genetic event, providing a proliferative signal to complement the physiology of Vhl loss, and
the opportunity for Vhl to contribute to the development of a highly vascular phenotype. Hence,
the AKT/mTOR signaling pathway, via activation of downstream HIF-1α regulatable genes
or by presenting a permissive environment in which a Vhl lesion can be maintained, may play
an integral role in the progression of VHL disease [28]. Future studies to determine whether
other genetic events can fill this role to cooperate with Vhl loss to promote tumor formation
are needed.
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In summary, we have developed a mouse model resembling human liver hemangioblastomas
by the combined conditional deletion of Vhl and Pten, which will be useful for understanding
the additive pro-angiogenic events of the two tumor suppressor genes and screening anti
angiogenesis drug treatments.
Acknowledgments
The work was supported by National Institutes of Health Grant R01-CA121781 (WKR). We thank the members of
Microscopy Services Laboratory in the Department of Pathology and Laboratory Medicine, University of North
Carolina at Chapel Hill for assistance.
References
1. McGrath FP, et al. Case report: multiple hepatic and pulmonary haemangioblastomas—a new
manifestation of von Hippel-Lindau disease. Clin Radiol 1992;45(1):37–39. [PubMed: 1740034]
2. Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997;76(6):381–391.
[PubMed: 9413424]
3. Chen F, et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor
suppressor gene. Cancer Res 1995;55(21):4804–4807. [PubMed: 7585510]
4. Gnarra JR, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7
(1):85–90. [PubMed: 7915601]
5. Shuin T, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor
suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54(11):2852–2855.
[PubMed: 8187067]
6. Rathmell WK, Simon MC. VHL: oxygen sensing and vasculogenesis. J Thromb Haemost 2005;3(12):
2627–2632. [PubMed: 15975138]
7. Brenner W, et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer
2002;99(1):53–57. [PubMed: 11948491]
8. Emerling BM, et al. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity
through Fork-head transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A 2008;105(7):2622–
2627. [PubMed: 18268343]
9. Rathmell WK, et al. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific
mutations. Cancer Res 2004;64(23):8595–8603. [PubMed: 15574766]
10. Lee CM, et al. VHL type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene
2009;28(14):1694–1705. [PubMed: 19252526]
11. Gnarra JR, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient
mice. Proc Natl Acad Sci U S A 1997;94(17):9102–9107. [PubMed: 9256442]
12. Haase VH, et al. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor
suppressor. Proc Natl Acad Sci U S A 2001;98(4):1583–1588. [PubMed: 11171994]
13. Ma W, et al. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis
in mice with conditional inactivation of the VHL gene. Cancer Res 2003;63(17):5320–5328.
[PubMed: 14500363]
14. Ding M, et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly
progressive glomerulonephritis in mice. Nat Med 2006;12(9):1081–1087. [PubMed: 16906157]
15. Frew IJ, et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst
formation. EMBO J 2008;27(12):1747–1757. [PubMed: 18497742]
16. McCarty DM, et al. Self-complementary recombinant adeno-associated virus (scAAV) vectors
promote efficient transduction independently of DNA synthesis. Gene Ther 2001;8(16):1248–1254.
[PubMed: 11509958]
17. McCarty DM, et al. Adeno-associated virus terminal repeat (TR) mutant generates self-
complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003;10
(26):2112–2118. [PubMed: 14625565]
18. Araki K, et al. Efficiency of recombination by Cre transient expression in embryonic stem cells:
comparison of various promoters. J Biochem (Tokyo) 1997;122(5):977–982. [PubMed: 9443813]
Chen et al. Page 9













19. Zolotukhin S, et al. Recombinant adeno-associated virus purification using novel methods improves
infectious titer and yield. Gene Ther 1999;6(6):973–985. [PubMed: 10455399]
20. Takeda S, et al. Successful gene transfer using adeno-associated virus vectors into the kidney:
comparison among adeno-associated virus serotype 1–5 vectors in vitro and in vivo. Nephron Exp
Nephrol 2004;96(4):e119–e126. [PubMed: 15122061]
21. Chen Z, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient
tumorigenesis. Nature 2005;436(7051):725–730. [PubMed: 16079851]
22. Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis
and treatment. Expert Rev Anticancer Ther 2008;8(1):63–73. [PubMed: 18095884]
23. Young AP, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and
p400. Nat Cell Biol 2008;10(3):361–369. [PubMed: 18297059]
24. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100(4):
387–390. [PubMed: 10693755]
25. Zundel W, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14(4):
391–396. [PubMed: 10691731]
26. Kim W, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen
sensing and cancer. Curr Opin Genet Dev 2003;13(1):55–60. [PubMed: 12573436]
27. Inoki K, et al. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37(1):
19–24. [PubMed: 15624019]
28. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene
2005;24(50):7455–7464. [PubMed: 16288292]
Chen et al. Page 10














Generation of the scAAV-Cre vector and hepatocyte's transduction. a pHpa-trs-SK plasmid
carrying GFP (scAAV-GFP); b scAAV-CRE, GFP was excised from the pHpa-trs-SK plasmid
and Cre substituted for GFP; c Reporter gene expression in the liver 4 weeks after scAAV-
GFP injected; d Frozen liver section X-gal stain 4 weeks after the scAAV-Cre vector injected
into ROSA26 reporter mice showing diffuse β-galactosidase positive hepatocytes, expression
of β-galactosidase indicated Cre-mediated excision of the loxP flanked stop signal and
hepatocytes have undergone Cre-mediated recombination; e H&E stain showed no
inflammatory cell infiltration in livers from scAAV-Cre injected mice. Magnification, ×100
(c through e)
Chen et al. Page 11














Comparison of external morphology and histological appearance of livers from AAV-Cre
vector injected VhlloxP/loxP (a, d, g), PtenloxP/loxP (b, e, h), and VhlloxP/loxP;PtenloxP/loxP (c, f,
i) mice. On gross examination, livers from AAV-Cre vector injected VhlloxP/loxP (a),
PtenloxP/loxP (b) appeared normal; livers from VhlloxP/loxP;PtenloxP/loxP mice (c) showed
irregular shape and multiple vascular lesions. Magnification, ×40 (d–f), ×100 (g–i)
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The highly vascular liver lesions from a VhlloxP/loxP;PtenloxP/loxP mouse were isolated by using
LCM. PCR analysis of recombination at the Vhl and Pten loci in the mice with recombination
of AAV-Cre vector, showing Vhl and Pten floxed, recombined, and wild type alleles,
respectively. (a) before dissection; (b) after dissection; (c) dissected tissue; (d) Vhl; (e) Pten
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PAS (a–c) and oil red O stain (d–f) of livers from AAV-Cre vector injected Vhl loxP/loxP (a,
d), Pten loxP/loxP (b, e), and VhlloxP/loxP;Pten loxP/loxP (c, f) mice demonstrate the presence of
glycogen (PAS) or lipid (oil red O stain). Magnification, ×200 (a through e) (Color figure
online)
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Immunohistochemical analysis of livers from VhlloxP/loxP (a), PtenloxP/loxP (b), and
VhlloxP/loxP;PtenloxP/loxP (c) mice using an antibody against the proliferation marker Ki-67.
d Quantification of the number of positive cells per high power field of the liver (×400). One
field per liver section was counted and the data represent mean ± standard deviation. *
Statistically significant difference between VhlloxP/loxP;PtenloxP/loxP and all other genotypes
(P < 0.01, student's t test). Magnification, ×200 (a through c)
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Immunohistochemical analysis of livers from AAV-Cre vector injected VhlloxP/loxP (a),
PtenloxP/loxP (b), and VhlloxP/loxP;PtenloxP/loxP (c) mice using an antibody against the
phosphorylated AKT. Panel b showed that phosphorylated AKT was sporadically positive in
livers from PtenloxP/loxP mice; Panel c showed phosphorylated AKT presence in hepatocytes
around the vascular lesions in VhlloxP/loxP;PtenloxP/loxP mice. Magnification, ×200 (a through
c)
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Immunohistochemistry stain of HIF-1α in livers from AAV-Cre vector injected VhlloxP/loxP
(a, d), PtenloxP/loxP (b, e), and VhlloxP/loxP;PtenloxP/loxP (c, f) mice. Panel c showed HIF-1α
expression upregulated in livers from VhlloxP/loxP;PtenloxP/loxP mice. d–f showed the
corresponding nuclear DAPI stain. Magnification, ×200 (a through f)
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Immunohistochemistry stain of HIF-2α in livers from AAV-Cre vector injected VhlloxP/loxP
(a, d), PtenloxP/loxP (b, e), and VhlloxP/loxP;PtenloxP/loxP (c, f) mice. Panel c showed HIF-2α
expression upregulated in livers from VhlloxP/loxP;PtenloxP/loxP mice. d–f showed the
corresponding nuclear DAPI stain. Magnification, ×200 (a through f)
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Immunohistochemistry stain of PECAM and VEGF in livers from AAV-Cre vector injected
VhlloxP/loxP (a, d), PtenloxP/loxP (b, e), and VhlloxP/loxP;PtenloxP/loxP (c, f) mice. c PECAM
expression upregulated in the liver vascular lesions from VhlloxP/loxP;PtenloxP/loxP mice. f
VEGF expression upregulated in the liver vascular lesions from VhlloxP/loxP;PtenloxP/loxP mice.
Magnification, ×200 (a through f)
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Table 1
Occurrence of liver pathology in conditional mutant mice
Genotyping No. of mice with described lesions Histopathology pathology Latency (months)
Pten loxP/loxP 18/20 Hepatocyte lipid 9
Pten loxP/loxP 2/20 Liver tumor 9
Vhl loxP/loxP ;Pten loxP/loxP 13/15 Vascular lesions 9
Vhl loxP/loxP ;Pten loxP/loxP 2/15 Hepatocyte proliferation Basophilic cell infiltration 9
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